¿¼²©±¨°à ¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ÿÈÕÇ©µ½
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æרҵ£º ;],Js1 m  
)ep1`n-  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Oxp!G7qfo  
T Ob(  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) ]3\%i2NM  
gTQc=,3l3  
1. ICAM-1 FX  %(<M  
h}U>K4BJ  
2. interleukin 12(IL-12) hh[@q*C  
1\X_B`xwD  
3. tumor infiltrating lymphocyte .WVIdVO7  
wVm QE  
4. TCR/CD3 complex xG1(vn83gq  
 3+/^  
5. hematopoietin receptor family ,@]*Xgt=  
d6XdN  
6. individual idiotype(IdI) )tv~N7  
vNQ|tmn  
7. integrin moD)^':.  
>H,5MM!  
8. colony-stimulatory factor (CSF) 6ltV}Wt-  
$YiG0GK<"  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© C*stj  
w y&yK*w  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? "!R*f $  
_/NPXDL  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ U.Fs9F4M#  
?P;=_~X  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷ÓᣠHBm(l@#.  
{ ^R r:+  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØϵ¡£ (7C$'T-ZK  
p+;;01Z+_  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) f{-,"6Y1  
}\QXPU{UVd  
1. ÊÔÊö¸ÉÈÅËصķÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌص㡣Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËؼì²âµÄ·½·¨ºÍÔ­Àí¡£ u`"Y!*[ -  
d~KTUgH'<  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ä¿Ç°¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æרҵ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) b Q-n<Lx  
w19OOD  
3. immunoglobulin superfamily (IgSF) Q2'`K|T  
Xdh@ ^`  
4. selectin +4F; m_G6  
F$S/zh$)0  
5. anti-idiotypic antibody (¦ÁId) \Rw^&;\1  
k)zBw(wr  
6. major histocompatibility complex(MHC) D7Y?$=0ycb  
t $PJ*F67M  
7. immunotolerance tm.&k6%  
1 J[z ![Tf  
8. biological reponse modifier(BRM) PHMp, z8  
ypNeTR$4  
9. immune reponse gene (Ir gene) i "aQm  
o\qeX|.70  
10. reshaped antibody (or reconstituted antibody) 4'.] -u  
p  ~)\!  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© Uv(}x 7e)  
q)PSHr=Z  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ mhF@S@  
m/WDJ$d  
2. ϸ°û¶¾ÐÔTÁÜ°Íϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? \}Kad\)  
r<;Y4<,BZ  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ 7'5/T]Z  
[-\DC*6  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? sA }X)aP  
/x /W>J2  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ 6wb M$|yFj  
w_YY~Af  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? 0.#% KfQ  
-./ Y  
2. Ä¿Ç°µ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ z]sQ3"cmX  
>Lz2zlZI  
¹©Ïû»¯ÄÚ¿ÆרҵÊÔÌ⣺ ltd'"J/r  
)Y?E$=M +B  
1. Ä¿Ç°ÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? b{ W ,wn  
S1!_ IK$m  
2. Ä¿Ç°µ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ V{0V/Nv  
n4 Y ]v  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æרҵ: *oIKddZh  
s'@@q  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: :Czvwp{z  
1xwq:vFC.  
ÃâÒßѧ  ^9kdd[  
NO#^_N`#\  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© ||?wRMV  
tWdP5vfp  
1. CD8 Sq 2yQSd  
uMP&.Y(  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) X .S8vlb4z  
3K_!:[  
3. immunoglobulin fold(Ig fold) QLTE`t5w3'  
WTh|7&   
4. cadherin (Ca-dependent cell adhesion moleculers) q}5&B =2pM  
/XW,H0pR  
5. idiotype-anti-idiotypic antibody immune network theory 4U:+iumy2  
^F1zkIE  
6. HLA class II antigen 9a_(_g>S  
=j~}];I  
7. complementarity-determining region (CDR) __||cQ  
0b}lwo,|\  
8. perforin(or pore-forming protein ,PFP) uO-R:MC  
:hxZ2O?5_  
9. high affinity IL-2 receptor w@ 2LFDp  
v]27+/a$c  
10. artificial active immunization %25_  
L jxn}):[  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© [G|2m_  
`o*g2fW!  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦ÓᣠrQ$A|GJL  
f1>^kl3@P  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 w02HSQ  
^ihXM]1{G  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ `ionMTZY  
osX23T~-  
4. ÊԱȽÏT¡¢BÁÜ°Íϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃ濹ԭ¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ F]?$Q'U  
*id|za|:k  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐÑ¡Ò»Ìâ,3¡¢4ÌâÖÐÑ¡Ò»Ìâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ä¿Ç°¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ JnY3]  
^! ZjK-$A<  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? {Q(6 .0R  
.Na>BR\F  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ W{m0z+N[B  
O x$|ZEh  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ #-HN[U?Gs  
3Yj}ra}  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ Nyqm0C6m^  
|f?C*t',  
ѧ¿Æרҵ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ g&E_|}u4  
47K5[R  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© lIFU7g  
/l$noask X  
1. immunoglobulin gene rearrangement Ju9v n44  
]VYl Eqe  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors)  B-gr2-  
;W*$<~_  
3. flow cytometry(FCM) eXaDx%mM  
TQ2Tt "  
4. carrier effect \4p<;$'  
t@HE.h  
5. positive selection of T lymphocytes in thymus 4 z`5W,  
hB+ t pa  
6. mouse TH1(Th1) and TH2(Th2) subsets SA7,]&Zb  
&^7)yS+C  
7. perforin (pore-forming protein ,PFP) N+V-V-PVk  
t3XMQ']  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) |5/[0V-vy  
mHMej@  
9. SH-2(src-homology region 2) XN0Y#l  
V V4_  
10. Ab2¦Â (internal image) C/Z"W@7#;  
yEny2q}  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© Mww]l[1'EL  
R`&ioRWj  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? \nyFN  
Ttj5% ~  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? !!86Sv  
W<L6,  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠ7GUJ&U) J  
V"ZbKV +[  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ bsr y([N>w  
Mt Z(\&~  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦ÓᣠEm;b,x*U  
4Dia#1$:J  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) ,')bO*N g  
M::iU_  
ÃâÒßѧרҵ£º jQ)>XOok  
;" *`  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ (r4VIlap  
QO.gt*"  
2. ÊԱȽÏÈËT¡¢BÁÜ°Íϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? wjJ1Psnx  
R6XMBYK^  
´«È¾²¡Ñ§×¨Òµ£º @RIEO%S  
0AKwZ' &H  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦ÄÜ¿É·¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ )1}g7:  
HJR<d&l ;p  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØϵ¡£ bl?%:qb.V  
ef;L|b%pp  
Ïû»¯×¨Òµ£º N08n/u&cr,  
fNPj8\#V,  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ w WU_?Dr_~  
8M9\<k6  
2.¼òÊöճĤÏà¹ØÁÜ°ÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌص㡣·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? k)V%.Eobf  
d %W}w.  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ J*!:ar  
!<zzP LC  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£©  MK"  
&AcFa<U  
1. Fas(CD95)/FasL }@%ahRGx%9  
dm=F:\C  
2. common chain of cytokine receptor gQ[^gPWP"  
N"RYM~c7  
3 . TCR/CD3 complex ;nKH m  
YG~ o  
4. negaive selection of thymocytes n qLAby_  
mv*T=N8fC  
5. artificial active immune MlK`sH6  
qf`xH"$  
6. anti-idiotypic +c8AbEewg  
,/`E|eG1G  
7. IgSF iEVA[ xy=D  
CEuk1$  
8. Integrin )_ ^WpyzF1  
CQzjCRS d  
9. chemokine cia-OVX  
<cv2-?L{  
10. B7/CD28 M2E87w  
25a#eDbqi  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© ^jha:d  
B >u,)  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ ,+/9K)X  
]\RSHz  
2. ±È½ÏCTLºÍNKɱÉË°Ðϸ°ûʱʶ±ðºÍɱÉË»úÖƵÄÌص㡣 Z-t}6c'Kg  
`e?;vA&  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ P,/13tZ#3  
2rO)qjiH  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆʵÑé·½°¸¿Ë¡´Ë»ùÒò¡£ &cu] vw  
N$%61GiulT  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ &*aer5?`  
O+o;aa6  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ nR o=J5tY  
9eGCBVW:*  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© s`#ntset0  
~Un64M?  
1. B7/CD28 E5*-;>2c  
}0BL0N`_  
2. Th1 subset 8lOZ IbwS  
|I}A> XG  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© "J P{Q  
_b0S  
4. antibody affinity maturation |7QVMFZ  
n5egKAgA  
5. AP-1 D|TLTF"  
6%ZHP?  
6. single chain variable fragment£¨ScFv£© [|a( y6Q  
@[d#mz  
7. NK cell receptor b&=]S(  
$R%+ *   
8. Zinkernagel-Doherty phenomenon "JzfL(yt  
0 &*P}U}Uc  
9. Ig fold H\)gE>  
/rIm7FW)  
10. CD40/CD40L =<[7J]%  
5mI?pfm  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© Az9X#h.vf  
rD0k%-{{  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØϵ¡£ PM~bM3Ei  
"?i>p z  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ ,dHP`j ?  
Y*Y&)k6 t  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹Øϵ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ rGTWcJ   
+jp|Y?6Z  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ X,>(Y8  
^pJ0nY# c  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁÜ°Íϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ |.j^G2x  
OYBotk]{1  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ C0zrXhY_v  
azvDvEWCQZ  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æרҵ£©¡£ nc< qbN  
Ru)(dvk}S  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© PPN q:,  
Qqp)@uM^  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© 2[.5oz`  
)j\r,9<K+5  
1.Co-stimulators (or co-stimulating molecules) ?^U c=  
`Gf{z%/  
2.NK-kB jUYF.K&  
fb /qoZ  
3.Immunoglobulin superfamily E\w+kAAf  
^Ss<X}es-  
4.antigen-presenting cell (APC) 2.]~*7   
Bk+{}  
5.death domain SAP;9*f1\  
#`vVg GZ&  
6.CCR and CXCR 5KK{%6#f\  
}bp.OV-+  
7.Lectin (or mitogen) ` %uK0qw"  
(JWv *p  
8.Clusters of differentiation, CD) D{>\-]\  
sqT^t!  
9.B7 family #7+]%;h  
WI6(#8^p  
10.Cytotoxic T lymphocyte, CTL) !Pw$48cg  
Uh*@BmDA  
11.IL-15 and IL-15 receptor (IL-15R) `6P?G|'   
_1P`]+K\D$  
12.MHC restriction |!oXvXU  
0#<WOns1   
13.Affinity-chromatography aF!WIvir  
b) Ux3PB  
14.Cyctosprin A, CsA nz[ m3]  
Y_+ SA|s  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) w?_`/oqd|  
ac|/Y$\w  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© P0)AU i  
GoazH?%  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 pUGN!3  
#v+;:  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØϵ¡£ K>$qun?5  
!O8.#+  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌص㡣 HJ",Sle  
~{$L9;x  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© L/%Y#  
?;_O 9  
ÃâÒßѧרҵ£º e+{BJN vz  
W6i3Psjsw  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ 1LX)4TCC  
R B%:h-t4  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ n7S; Xve#  
@i{]4rk lv  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎΪÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ i&*<lff  
Zt_r9xs>  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) 2qjyFTT  
bJPJ.+G7  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) w{r8kH  
] );NnsG  
1. ADCC(antibody dependent cell-mediated cytotoxicity) Cdmy.gx^  
},s_nJR:8  
2. »·æß¾úËØ(cyclosporin) n$xszuNJ`  
fdLBhe#9M  
3. KIR(killer cell inhibitory receptor) Se Oy7  
,\x$q'  
4. HLDA(human leucocyte differentiation antigen) #QS?s8IrW  
-x5F;d}  
5. Interleukin 18(IL-18) FB_NkXR  
bJ6p,]g  
6. ÕûºÏËØ(integrin) X.eB ;w/}  
O J>iq@ >  
7. Fas/FasL 7f r>ZY^  
(0}j]p'w  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) |T y=7d,  
g>T  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) USFg_sO  
#N9d$[R*  
10. Th1/Th2 xl,ryc3J  
$ 9=8@  
11. »ùÒòÒßÃç(DNAÒßÃç) yquAr$L!  
7>mhK7l  
12. chemokines and chemokine receptor #R< G,"N5  
mLaCkn  
13. ÃâÒßÄÍÊÜ '$6PTa  
bl$j%gI%,  
14. ¹²´Ì¼¤·Ö×Ó sv`"\3N[  
;W6-i2?  
15. ËÀÍö½á¹¹Óò(death domain) >f%,`r  
x? =B\8m  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) =y<0UU  
Ro~fvL~Ps  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉË°Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? [zx|eG<&-  
N%*9&FjrL  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»Æƶø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óᣠh1c{?xH2r  
Kr]W o8dWy  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î !t% Q{`p  
/tzlbI]z  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ QoWR@u6a  
Ck@M<(x  
£¨3£©1984Ä꣺ÁÜ°Íϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå :~er h}~ps  
` yYvYc  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄЩÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ zQ<88E&&Xs  
"qE {a>d  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) 0O[l?e4,8{  
yf?W^{^|  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ I{EI HD<  
+ ~~ Z0.[  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ iJ4 <f->t  
}k| g%H J  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆһϵͳʵÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃÇ°¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
Ãâ·Ñ¿¼²©ÍøÍøÖ·ÊÇʲô? ÕýÈ·´ð°¸:freekaobo.com
°´"Ctrl+Enter"Ö±½ÓÌá½»